$261 Million is the total value of SV Health Investors, LLC's 6 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ENTL | ENTELLUS MEDICAL INC | $90,274,000 | +18.1% | 3,489,533 | 0.0% | 34.56% | +36.9% | |
| OPHT | Sell | OPHTHOTECH CORPORATION | $72,742,000 | -23.9% | 1,397,256 | -31.9% | 27.85% | -11.8% |
| OCUL | Sell | OCULAR THERAPEUTIX INC | $40,643,000 | -62.6% | 1,932,607 | -25.3% | 15.56% | -56.6% |
| CATB | New | CATABASIS PHARMACEUTICALS, INC. | $34,892,000 | – | 2,857,667 | +100.0% | 13.36% | – |
| TRXC | TRANSENTERIX INC | $22,640,000 | +2.4% | 7,546,692 | 0.0% | 8.67% | +18.6% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- SVLSF IV, LLC #1
- SV Life Sciences Fund IV (GP), L.P. #2
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TRANSENTERIX, INC. | 27 | Q4 2020 | 24.0% |
| OCULAR THERAPEUTIX, INC. | 24 | Q2 2020 | 35.9% |
| KALVISTA PHARMACEUTICALS INC | 17 | Q4 2020 | 31.0% |
| DECIPHERA PHARMACEUTICALS INC | 17 | Q3 2021 | 31.0% |
| CATABASIS PHARMACEUTICALS, INC. | 15 | Q4 2018 | 18.2% |
| X4 PHARMACEUTICALS INC | 15 | Q3 2022 | 3.2% |
| BICYCLE THERAPEUTICS PLC | 14 | Q3 2022 | 65.4% |
| SUTRO BIOPHARMA INC | 14 | Q4 2021 | 19.1% |
| ENTELLUS MED INC | 12 | Q4 2017 | 64.4% |
| AVROBIO INC | 12 | Q1 2021 | 41.6% |
View SV Health Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-07 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-14 |
View SV Health Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.